Aging is driven by hallmarks fulfilling the following three premises:(1) their age-associated
manifestation,(2) the acceleration of aging by experimentally accentuating them, and (3) the …

Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome
resistance to immune checkpoint inhibitors in patients with refractory melanoma; however …

Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
shaping cancer immunosurveillance and response to immunotherapy. Our understanding of …

The gut microbiota shapes the response to immune checkpoint inhibitors (ICIs) in cancer,
however dietary and geographic influences have not been well-studied in prospective trials …

The use of probiotics by cancer patients is increasing, including among those undergoing
immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host …

High-throughput methods to investigate tumour omic landscapes have quickly catapulted
cancer specialists into the precision oncology era. The singular lesson of precision oncology …

Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of
cancer therapy, most notably immunotherapy and its immune-related adverse effects. The …

Colorectal cancer (CRC) is one of the commonest cancers globally. A unique aspect of CRC
is its intimate association with the gut microbiota, which forms an essential part of the tumour …